LSD恢复了用吗啡治疗小鼠的VTA中的突触可塑性,并破坏了吗啡条件下的位置偏好
Michael Von Gunten1, Tenna Russell1, Isaac Stirland2
1Brigham Young University, Neuroscience Center, Provo, UT 84602 USA.
bioRxiv : the preprint server for biology
|July 15, 2025
概括
Lysergic acid diethylamide (LSD) 可能会逆转药物诱导的大脑变化. 这项研究表明,LSD可以恢复塑性,并减少小鼠对吗啡的偏好,为物质使用障碍治疗提供了潜在的可能性.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 迷幻药对神经精神疾病有很大的前景.
- 治疗效果可能来自于逆转不适应性可塑性.
- 吗啡依赖是一个重大的公共卫生问题.
研究的目的:
- 研究 lysergic acid diethylamide (LSD) 对用吗啡治疗的小鼠的生理,行为和表观遗传影响.
- 为了确定LSD是否可以逆转吗啡引起的大脑可塑性和行为的变化.
主要方法:
- 用吗啡治疗的雄性和雌性小鼠接受了单次高剂量或LSD的微剂量.
- 行为评估包括有条件的位置偏好.
- 电生理学 (全细胞) 检查了VTA GABA神经元中的突触可塑性.
- 进行了全脑DNA甲基化分析.
主要成果:
- 液治疗加快了吗啡诱导的有条件偏好地方的灭绝.
- 一次高剂量的LSD恢复了VTA GABA神经元中的激发性突触可塑性,而这种可塑性因吗啡而受损.
- 液治疗导致全脑DNA甲基化概况的显著差异.
结论:
- Lysergic acid diethylamide (LSD) 可能可以逆转或防止吗啡诱导的奖励电路可塑性的改变.
- LSD显示出对吗啡偏好和成的缓解措施的潜力.
相关概念视频
Long-term Depression
31.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
31.5K
Long-term Potentiation
55.8K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
55.8K
Drug Abuse and Addiction: Pharmacological Phenomena
659
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
659
Analgesia and Pain Management
811
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
811
Hallucinogens and Psychedelics
287
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
287
Opioid Receptors: Overview
1.9K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
1.9K


